Imatinib (Gleevec), a well-known FDA-approved BCR-ABL fusion protein inhibitor for treatment of Philadelphia chromosome positive chronic myelogenous leukemia (CML), targets the tyrosine kinase domain on the ABL side56. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.